Research programme: clopidogrel nano-emulsion - Ascendia PharmaceuticalsAlternative Names: ASD-002
Latest Information Update: 11 Jan 2017
At a glance
- Originator Ascendia Pharmaceuticals
- Class 2 ring heterocyclic compounds; Antiplatelets; Chlorobenzenes; Esters; Pyridines; Small molecules; Thienopyridines
- Mechanism of Action Platelet ADP receptor antagonists; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Acute coronary syndromes